The development of deoxynyboquinone as a personalized anticancer compound

The major challenge in cancer therapy is to selectively destroy cancer cells in the presence of healthy tissue. One viable strategy relies on targeting the function of an enzyme which is overexpressed in cancer cells relative to healthy cells. NQO1 is a cytoprotective enzyme which is overexpressed in most solid tumors and which detoxifies quinone-containing substrates. However, a few quinones are rendered more toxic by the action of NQO1. We discovered that deoxynyboquinone (DNQ) is a potent cytotoxin through a high-throughput screen, and we designed a concise and flexible synthesis of this molecule which enabled study of its mode of action. We found that DNQ generates toxic levels of reactive oxygen species (ROS) selectively in cancer cells through a bioreduction/oxidation process mediated exclusively by NQO1. Excitingly, DNQ is effective at reducing the size of tumors in a mouse model of cancer. Unfortunately, DNQ must be delivered at concentrations near the maximum tolerated dose in mice to achieve maximal efficacy. In addition, the poor aqueous solubility of DNQ necessitated the use of a formulation containing a high concentration of 2-hydroxypropyl-b-cyclodextrin (HPbCD) which would complicate treatment in human patients. Thus, we set out to discover derivatives of DNQ which are more soluble than, and equipotent to, the parent compound. We synthesized and evaluated a library of DNQ derivatives and determined the structure-activity and structure-solubility relationships derived therefrom. We showed that a subset of these derivatives are equipotent to DNQ and are up to 4-fold more soluble in water, 250-fold more soluble in organic solvents, and 9-fold more soluble in an aqueous solution of HPbCD. Furthermore, we showed that the most promising of these derivatives are tolerated by mice at doses up to 4-fold higher than DNQ. We predict that derivatives of DNQ will exhibit a broad therapeutic window in murine tumor models of cancer and will progress rapidly toward human clinical trials.

Name thesis:degree_name

Ph.D.

Level thesis:degree_level

Dissertation

Discipline thesis:degree_discipline

Chemistry

Grantor

University of Illinois at Urbana-Champaign

Year dc:date

2012

Author dc:creator

• Bair, Joseph

Contributors dc:contributor

• Hergenrother, Paul J.
• Denmark, Scott E.
• Katzenellenbogen, John A.
• Rauchfuss, Thomas B.

• Cancer
• personalized medicine
• quinone
• total synthesis
• reactive oxygen species
• NQO1

Statement dc:rights

• Copyright 2012 Joseph Bair

Language dc:language

en

Handle dc:identifier

http://hdl.handle.net/2142/32020

OAI identifier oai:identifier

oai:www.ideals.illinois.edu:2142/32020